WONDFO BIOTECH(SZ:300482) Chang Jiang Shang Bao·2025-09-25 02:54Core Viewpoint - Wanfu Bio plans to repurchase shares to boost investor confidence, with a total repurchase amount between 30 million and 60 million yuan, and a maximum price of 34.66 yuan per share [2] Group 1: Share Repurchase Details - The repurchase will involve approximately 865,600 to 1,731,100 shares, accounting for 0.18% to 0.37% of the company's total share capital [2] - The repurchase period is set for six months from the board's approval date [2] - The funding for the repurchase will come from the company's own funds, with the maximum repurchase amount representing 0.87% of total assets and 1.08% of net assets as of June 30, 2025 [2] Group 2: Company Background and Performance - Wanfu Bio, established in 1992 and listed in 2015, is a leading player in China's in vitro diagnostics sector, particularly in the POCT industry [3] - In the first half of 2025, the company faced significant challenges, with revenue dropping to 1.246 billion yuan, a year-on-year decrease of 20.92%, and net profit falling to 189 million yuan, down 46.82% [3] - The company has increased its R&D investment as a core strategy to address industry pressures, with total R&D spending from 2022 to the first half of 2025 amounting to 1.513 billion yuan [4] Group 3: R&D Achievements - Wanfu Bio has made significant advancements in strategic areas, particularly in the field of chemiluminescence, launching the LA-6000 laboratory intelligent assembly line [4] - The company has optimized product performance to meet the demand for instant and small-scale testing, gradually replacing traditional testing solutions [4] - As of June 30, 2025, Wanfu Bio holds 490 valid patents, including 141 invention patents, 264 utility model patents, and 85 design patents [4]